Although hemophilia B affects 1 in 25,000 males there may be 3 female hemophilia B carriers per affected male. This clinical review highlights the unique challenges faced by hemophilia B carriers including the under-recognition of bleeding symptoms associated with and without FIX deficiency, discrepancies in correlation between genotype and bleeding phenotype and therapeutic considerations utilizing clinical vignettes of common scenarios.
B carriers with factor IX [FIX] levels <or ≥50%, von Willebrand disease, qualitative platelet disorders) often overlap and may include heavy menstrual bleeding, postpartum haemorrhage and postoperative bleeding. Typically, the severity and frequency of these symptoms are more prominent in individuals with a haemostatic defect; however, the underlying aetiology may go uninvestigated. 2 Haemophilia has historically been considered a "male disease" since it results from pathological variants of the F8 or F9 gene on the X chromosome. Additionally, until recently it was assumed that females who inherit a haemophilia pathologic variant should be protected from factor deficiency due to the normal factor protein synthesis supported by the unaffected F8 or F9 gene. 3 Despite this, mild haemophilia (FIX 6%-49%) and in rare cases more severe forms of haemophilia can occur in females.
Although several country specific registries capture the spectrum of bleeding severity in congenital bleeding disorders it is clear there is a focus on those with a more severe bleeding phenotype. In the U.S., the first concerted effort in surveillance was via the Universal Data Collection (UDC) project, which ended in 2011. This was followed by the current Centres for Disease Control (CDC) Community
Counts project. Unfortunately, the UDC only captured data from federally funded haemophilia treatment centres and the initial focus was on males with haemophilia. CDC Community Counts has rectified this with prospective collection of both men and women with FVIII and FIX deficiency. As of December 2016, this registry includes 532 females with FIX deficiency. 4 Additionally, the Canadian Bleeding Disorders Registry and the UK Haemophilia Centre Doctors
Organization report 93 and 256 females with FIX levels less than 40%
respectively. 5, 6 These data do not include haemophilia carriers who may seek medical attention for bleeding symptoms in the setting of a normal haemostatic factor level (FIX ≥ 50%). Non-obligate haemophilia carriers with normal factor levels and no bleeding symptoms are likely to remain unidentified. 7 Increased access to genotyping
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| GENOTYPE VS PHENOTYPE: BLEEDING VARIABILITY IN HAEMOPHILIA B CARRIERS
Over 1000 pathologic variants in the F9 gene, most commonly missense, have been identified impacting all key functional domains. 8, 9 A number of published databases, including data from the CDC Haemophilia B Mutation Project (CHBMP) mutation database, which
excluded female carriers, demonstrate the heterogeneity in male haemophilia severity for any given type pathologic variant. 8 The designation of carrier refers to the presence of a recessive pathologic variant on the X-chromosome. While this heterozygous genotypic status is typically considered non-pathologic, in some cases a disease phenotype can occur, thus the carrier status has important implications for genetic counselling and patient education. The term "symptomatic carrier" in haemophilia is often applied loosely and may refer to an obligate or genetically verified female haemophilia carrier who reports any prior bleeding symptoms, or may be more stringently applied to known female carriers who have demonstrated FIX levels below the normal range. The authors suggest the term "symptomatic haemophilia carrier" should be considered in carriers with normal levels (FIX ≥ 50%) and a bleeding tendency with clarification to be conducted via ISTH in the upcoming year.
Clinical vignette: A 6-year-old female was recently seen in hematology clinic for evaluation due to her mother's concern for symptoms of frequent bruising with physical activity and recurrent epistaxis. This young girl required a tonsillectomy. The mother was not aware that her daughter's bleeding tendency may be due low factor IX levels or her family history of haemophilia B. The aPTT was normal at 38 seconds. FIX activity was 52%. Although her levels were at the low end of the current normal range, she may be at risk for surgical bleeding based on published literature. She was assigned a diagnosis of "symptomatic haemophilia B carrier" indicating her bleeding tendency despite a FIX level of ≥50%.
Haemophilia carriers may have a normal non-bleeding phenotype, haemophilia-like, or bleeding symptoms not clearly explained by factor activity that warrant additional evaluation. Contributing to terminology confusion is the variable factor activity level range ascribed to the threshold between normal and mild deficiency with haemophilia. Most all scales denote less than 1% factor activity as severe haemophilia and 1%-<5% activity as moderate; however, the upper end of the mild severity range varies between 40%-50% depending on the referenced used. 3, 10 While awaiting confirmation genetically, a FIX activity level cut-off of 75% may provide acceptable sensitivity and specificity to discriminate between carriers and non-carriers.
11
According to the Lyon hypothesis there is random inactivation of the X-chromosome leading to residual FIX activity of ~50%. Skewed (nonrandom) inactivation of the unaffected X chromosome during embryogenesis (lyonization) is the most common explanation for why FIX deficiency (<40%-50%) occurs in a female haemophilia B carrier. The impact of this mosaicism with respect to FIX production depends on which tissues are affected. Other more rare aetiologies of haemophilia B in a female include compound heterozygosity for pathologic haemophilia variants, Turner syndrome, severe unequal X inactivation due to twinning, transgender (4 patients in the ATHNdataset currently), or rare testicular feminization. 12 The clinical implication of these phenomena is nicely illustrated by the published report of two sisters who presented with bleeding symptoms of different severities in a family with no history of bleeding disorders.
One sister had moderate-severe FIX deficiency (FIX level 1%) and the other had mild FIX deficiency with a baseline FIX level of 7%. Both sisters were found to have inherited a null mutation from their mother who was clinically asymptomatic and had a normal coagulation profile. Skewed X inactivation led to mild FIX deficiency in one sister while the other sister acquired a missense mutation in exon 8 of her other F9 gene resulting in a compound heterozygote state and moderate-severe FIX deficiency.
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Bleeding variability has also been described among individuals possessing the same F9 gene variant. Sixty-four haemophilia B carriers in a large Amish pedigree in Ohio with a single common founder mutation F9: p.thr296met were investigated for bleeding phenotype.
A subset of 32 participants was analyzed for menstrual symptoms.
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Among the subjects in this cohort, the median FIX level was 45%
(range 19%-114%), and 19 (29.6%) of the patients had baseline FIX level <40%. The bleeding scores associated with FIX levels are illustrated in Figure 1 . 13 This variation parallels the observations made in a multinational study quantifying abnormal bleeding symptoms in haemophilia carriers, in whom marked heterogeneity of bleeding scores is observed across the range of baseline FIX levels. 14 In the Amish population cohort, a total of 12 women had total bleed scores ≥3. All of these women reported bleeding from at least 2 sites, and they had significantly reduced mean FIX levels compared with those with bleed scores <3 (42 ± 10.3% vs 54.7 ± 22%, respectively; P = .002). Dental extraction bleeding requiring treatment, heavy menstrual bleeding, and postpartum haemorrhage were the predominant bleeding sequela for women with mild haemophilia B and bleeding scores ≥3.
The mechanisms underlying the heterogeneity seen in the bleed- 
| BLEEDING PATTERNS IN HAEMOPHILIA B CARRIERS
Although increased bleeding was recognized in some haemophilia carriers in the 1950s, 17 available data on frequency and severity of bleeding symptoms in haemophilia B carriers in general, and those also with mild Study dataset of age-related joint ROM of non-carrier females developed by the CDC. 16 The proportion of females reporting ≥1 joint bleed in the preceding 6 months rose with increasing haemophilia severity-2%, 33%, and 37% for mild, moderate, and severe FIX deficiency respectively and 15%, 36%, and 54% for mild, moderate, and severe FVIII deficiency respectively. 16 The patterns of total joint ROM changes across all age ranges for non-carriers and haemophilia B carriers are listed in Table 1 . Across age ranges and severity strata, between-group differences remained statistically significant by multivariate analysis after controlling for BMI and race. 16 Although conducted only in haemophilia A carriers and unknown whether we can extrapolate, 9 obligate carriers (median age 40 years) with normal levels (median FVIII level 89%) from
Vanderbilt University had MRI evidence of early structural joint changes that were highly likely to be attributed haemophilia carriage.
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A separate study of patients in the UDC database showed that females with factor levels in the moderate and severe deficiency range had comparable bleeding histories as those observed in males. 21 Although there were few female haemophilia B carriers with and without normal FIX levels in the UDC database, the proportion of haemophilia B in these patients was consistent with its prevalence in the male population (females: 5/22, 22%; males: 2413/11053, 22%). The frequency of joint bleeds was high in female cohorts (moderate: 7/8, 88%;
severe: 13/14, 93%), consistent with prior analysis [17] . Interestingly, the frequency of HMB was lower than in previous studies (4/15, 27%);
however, this could be attributed to the fact that the haemophilia forms focused on male gender bleeding and did not inquire about reproductive tract bleeding. The most consistent difference between the male and female cohorts was older age at diagnosis in females.
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T A B L E 1 Range of motion (ROM) difference among females with FIX deficiency by age and factor activity (reproduced with permission from Gilbert et al 20 
)
Age (years) n FIX ≥40% n FIX >5%-<40% n FIX ≥1%-≤5% n FIX <1% In evaluating the studies on bleeding tendency, it should be emphasized that despite the generally high quality of these studies, the number of included haemophilia B carriers remains relatively small.
Chance factors and selection bias may impact the generalizability of bleeding phenotypes observed in haemophilia carriers and females with haemophilia B. After failing multiple hormonal options, she began infusing a rFIX concentrate 80 units/kg on day 1 and 3 of her menstrual cycle with reduction in her periods to two 50% saturated pads a day for 5 days.
| DIAGNOSTIC CONSIDERATIONS
In clinical practice, recognition of mild FIX deficiency in females may be complicated by a normal PTT and lack of provider acknowledge that the possibility of mild to severe deficiency is scientifically plausible. The interval between the onset of bleeding symptoms and diagnosis of a bleeding disorder such as mild FIX deficiency is often prolonged. In one study, the mean age of diagnosis for haemophilia carriers with severe FIX deficiency was 8.5 months, compared to 2 months for similarly affected males. The difference was even more pronounced for cases of moderate FIX deficiency at 48 vs 9 months respectively. 21 When accounting for all bleeding disorders, women may have a 16-year delay from the time of bleeding symptom onset to diagnosis. 22, 23 Adolescents with HMB may not be identified to have mild FVIII/FIX deficiency owing to the much higher prevalence of von Willebrand disease (VWD) and qualitative platelet disorders that potentially extend the time to diagnosis further. 24 Delayed diagnosis of a bleeding disorder in carriers is likely due to different diagnostic evaluations and physician referral patterns. Delayed diagnosis puts affected females at risk for increased morbidity and even mortality depending on the clinical context. HMB can have a significant impact on missed days at school/work, impaired quality of life, iron deficiency anaemia, and need for blood transfusions or hospitalization. 2 Certainly, bleeding symptoms such as HMB, hemopertioneum from a ruptured ovarian cyst, postpartum haemorrhage, abnormal mucocutaneous, posttraumatic or postsurgical bleeding, or unexplained iron deficiency anaemia should prompt a provider to investigate for an underlying bleeding disorder including VWD, coagulation factor deficiency, or platelet function defects. 24 Due to the laboriousness and cost of special coagulation laboratory testing a staged diagnostic approach is prudent.
In summary, the aforementioned studies demonstrate that there is an increased frequency of bleeding symptoms in haemophilia carriers extending to those with normal FIX levels. While some healthcare providers advocate a need to redefine the normal range of FIX levels, our ability to assay the multitude of components integral to effective haemostasis remains limited. Improvements in the diagnostic evaluation of bleeding symptoms that occur in carriers and women without a defining haemostatic defect will rely on increased understanding of the polymorphisms and pathologic variants that impact the fibrinolytic system, platelet function and coagulation protein interactions, VWF and collagen interactions as bleeding, like thrombosis, can certainly be a multi-factorial process. Studies predicting bleeding risk in women and girls, with a factor IX variant, based on measure of global coagulation such as thrombin generation and thromboelastography are in order.
| MANAGEMENT CONSIDERATIONS
Haemostatic plans for haemophilia carriers with mild to severe FIX de- mild, moderate and severe deficiency. 7 Additionally, they suggest that factor IX replacement should be considered prior to surgery or with significant bleeding symptoms for haemophilia B carriers with factor levels less than 60%, 7 ( Table 2 ).
Haemophilia carriers of child-bearing age with mild to severe FIX deficiency are at increased risk of PPH. 25 Unlike FVIII and VWF, which typically rise particularly during the third trimester and may reach sufficient haemostatic levels even for those with a baseline mild deficiency, FIX levels do not rise significantly during pregnancy. 26 Specific guidance for target peri-partum FIX levels and the duration of FIX elevation is lacking. Furthermore, there are no data on the change in FIX activity immediately following pregnancy although this is assumed to remain stable. Replacement with exogenous plasma-derived or recombinant factor IX concentrates may be necessary targeting a level of at least 50% with epidural anaesthesia and for vaginal delivery or cesarean delivery. 27 A retrospective survey of 46 haemophilia carriers in a Dutch cohort revealed that nearly half were unaware that they were obligate carriers at time of first pregnancy. 28 In this cohort, primary or secondary bleeding events complicated 15% of deliveries and 23% of women experienced peripartum bleeding complications.
Stoof and colleagues also observed high rates of PPH during deliveries and severe PPH (both about 33%) in three obstetrical centres in the Netherlands. 29 Their results, acknowledging their liberal definition of PPH, suggest a higher target factor level >100% postpartum may be necessary. In this study Stoof and colleagues defined PPH as ≥500 mL and severe PPH as ≥1000 mL, both of which are debatable as pathologic thresholds. Duration of sustainment of FIX in the haemostatic range is recommended for 3-4 days for vaginal delivery and 5-7 days for C-section. 30 Monitoring for persistence of bleeding symptoms following hospital discharge is necessary in this population to ensure that additional intervention is not needed. 
